190 related articles for article (PubMed ID: 37639602)
1. A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer's disease.
Chen ZL; Singh PK; Calvano M; Norris EH; Strickland S
Proc Natl Acad Sci U S A; 2023 Sep; 120(36):e2309389120. PubMed ID: 37639602
[TBL] [Abstract][Full Text] [Related]
2. Lecanemab demonstrates highly selective binding to Aβ protofibrils isolated from Alzheimer's disease brains.
Johannesson M; Söderberg L; Zachrisson O; Fritz N; Kylefjord H; Gkanatsiou E; Button E; Svensson AS; Rachalski A; Nygren P; Osswald G; Lannfelt L; Möller C
Mol Cell Neurosci; 2024 Jun; 130():103949. PubMed ID: 38906341
[TBL] [Abstract][Full Text] [Related]
3. Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta.
Rofo F; Buijs J; Falk R; Honek K; Lannfelt L; Lilja AM; Metzendorf NG; Gustavsson T; Sehlin D; Söderberg L; Hultqvist G
Transl Neurodegener; 2021 Sep; 10(1):38. PubMed ID: 34579778
[TBL] [Abstract][Full Text] [Related]
4. Lecanemab blocks the effects of the Aβ/fibrinogen complex on blood clots and synapse toxicity in organotypic culture.
Singh PK; Simões-Pires EN; Chen ZL; Torrente D; Calvano M; Sharma A; Strickland S; Norris EH
Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2314450121. PubMed ID: 38621133
[TBL] [Abstract][Full Text] [Related]
5. The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII.
Zamolodchikov D; Renné T; Strickland S
J Thromb Haemost; 2016 May; 14(5):995-1007. PubMed ID: 26613657
[TBL] [Abstract][Full Text] [Related]
6. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L
Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511
[TBL] [Abstract][Full Text] [Related]
7. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease.
Ono K; Tsuji M
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023927
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
[TBL] [Abstract][Full Text] [Related]
9. The conformational epitope for a new Aβ42 protofibril-selective antibody partially overlaps with the peptide N-terminal region.
Colvin BA; Rogers VA; Kulas JA; Ridgway EA; Amtashar FS; Combs CK; Nichols MR
J Neurochem; 2017 Dec; 143(6):736-749. PubMed ID: 28881033
[TBL] [Abstract][Full Text] [Related]
10. Isolated amyloid-β(1-42) protofibrils, but not isolated fibrils, are robust stimulators of microglia.
Paranjape GS; Gouwens LK; Osborn DC; Nichols MR
ACS Chem Neurosci; 2012 Apr; 3(4):302-11. PubMed ID: 22860196
[TBL] [Abstract][Full Text] [Related]
11. Dihydrochalcone molecules destabilize Alzheimer's amyloid-β protofibrils through binding to the protofibril cavity.
Jin Y; Sun Y; Lei J; Wei G
Phys Chem Chem Phys; 2018 Jun; 20(25):17208-17217. PubMed ID: 29900443
[TBL] [Abstract][Full Text] [Related]
12. Abundant Aβ fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer's disease brains.
Stern AM; Yang Y; Jin S; Yamashita K; Meunier AL; Liu W; Cai Y; Ericsson M; Liu L; Goedert M; Scheres SHW; Selkoe DJ
Neuron; 2023 Jul; 111(13):2012-2020.e4. PubMed ID: 37167969
[TBL] [Abstract][Full Text] [Related]
13. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.
Tucker S; Möller C; Tegerstedt K; Lord A; Laudon H; Sjödahl J; Söderberg L; Spens E; Sahlin C; Waara ER; Satlin A; Gellerfors P; Osswald G; Lannfelt L
J Alzheimers Dis; 2015; 43(2):575-88. PubMed ID: 25096615
[TBL] [Abstract][Full Text] [Related]
14. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy.
Harper JD; Wong SS; Lieber CM; Lansbury PT
Chem Biol; 1997 Feb; 4(2):119-25. PubMed ID: 9190286
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-β(1-42) protofibrils formed in modified artificial cerebrospinal fluid bind and activate microglia.
Paranjape GS; Terrill SE; Gouwens LK; Ruck BM; Nichols MR
J Neuroimmune Pharmacol; 2013 Mar; 8(1):312-22. PubMed ID: 23242692
[TBL] [Abstract][Full Text] [Related]
16. The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention.
Tolar M; Hey JA; Power A; Abushakra S
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473975
[TBL] [Abstract][Full Text] [Related]
17. Nordihydroguaiaretic acid does not disaggregate beta-amyloid(1-40) protofibrils but does inhibit growth arising from direct protofibril association.
Moss MA; Varvel NH; Nichols MR; Reed DK; Rosenberry TL
Mol Pharmacol; 2004 Sep; 66(3):592-600. PubMed ID: 15322251
[TBL] [Abstract][Full Text] [Related]
18. Lecanemab Blocks the Effects of the Aβ/Fibrinogen Complex on Blood Clots and Synapse Toxicity in Organotypic Culture.
Singh PK; Pires ENS; Chen ZL; Torrente D; Calvano M; Sharma A; Strickland S; Norris EH
bioRxiv; 2024 Jan; ():. PubMed ID: 38293058
[TBL] [Abstract][Full Text] [Related]
19. A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease.
Lannfelt L
Ups J Med Sci; 2023; 128():. PubMed ID: 38084203
[TBL] [Abstract][Full Text] [Related]
20. Development of β-sheet structure in Aβ aggregation intermediates diminishes exposed hydrophobic surface area and enhances proinflammatory activity.
Dhami KB; Karki S; Parks A; Nichols CG; Nichols MR
Biochim Biophys Acta Proteins Proteom; 2022 Sep; 1870(9):140817. PubMed ID: 35905824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
